Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
Tony Mira: Analyzing Anesthesiologists’ Investments in ASCs
Mylan’s Generic Anesthesia Drug Approved by FDA
Mission Hospital Renews Partnership With Asheville Anesthesia Associates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
